Pharmacology

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Business #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #High throughput screening #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Pharmacology #Pharmokinetics #Regulatory #RNA #Screening #Target validation #Toxicology

Applications of liquid chromatography mass spectrometry

Applications of liquid chromatography mass spectrometry By Dr David Kwok Applications of liquid chromatography mass spectrometry in accelerating the pace of lead-drug candidate selection and pre-clinical development. This review discusses how the application and benefits of using LC/MS and LC/MS/MS assays in conjunction with in vivo and in vitro study… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Cell therapy #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Gene therapy #Genomics #Lead discovery #Lead optimisation #Patent Law #Pharmacology #Preclinical #Screening #Stem cells #Therapeutics

Failure rates in drug discovery and development: will we ever get any better?

Failure rates in drug discovery and development: will we ever get any better? By William Bains Drug discovery is an expensive, slow and risky business. An analysis which takes into account projects which neither succeed nor fail suggests that it costs more than $1 billion to launch a technically successful… Read More

#Archive

#Analysis #Animal models #Biochemistry #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #Imaging #Lead discovery #Pathology #PCR #Pharmacology #RNA #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Novel concepts and therapeutic options for the treatment of schizophrenia

Novel concepts and therapeutic options for the treatment of schizophrenia By Dr Karoly Nikolich and Dr Roman Urfer Schizophrenia affects a large number of individuals irrespective of social status and education. Current treatments of schizophrenia represent the second largest central nervous system (CNS) pharmaceutical market, exceeding $12 billion per year. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Automation / robotics #Biomarkers #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #Lead discovery #Medicinal chemistry #Metabolomics #Molecular medicine #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology #Target validation #Toxicology

Metabonomics – A generic platform for the investigation of drug toxicity, altered gene function and disease processes

Metabonomics - A generic platform for the investigation of drug toxicity, altered gene function and disease processes By Professor Jeremy K. Nicholson Metabonomics can offer one of the most complete solutions to tackling one of the pharmaceutical industry's biggest problems attrition. This article discusses the scope and uses of metabonomics… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Business #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #Pharmacology #Pharmokinetics #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics

Virtual Screening – Finding needles in a haystack on a shoestring

Virtual Screening - Finding needles in a haystack on a shoestring By Dr David E. Clark, Neil V. Harris, Alan G. Roach and Dr Anthony D. Baxter In recent years, virtual screening (VS) has become an accepted approach to hit-finding alongside biochemical high-throughput screening (HTS). Large pharmaceutical companies are typically… Read More

#Archive

#AI / data analytics / healthtech / informatics #Business #Clinical trials #Drug development #Drug discovery #Immunology / Virology & Vaccines #Lead discovery #Pharmacology #Regulatory #RNA

How can we build sustainable European biopharmaceutical companies?

By Professor Simon Turton, Henry Makansi and Nick Lowcock Business models for emerging bioscience companies come in and out of fashion with some regularity, not always with obvious reason. This article examines what strategies have worked for the leading biopharmaceutical firms in Europe to try to identify what lessons there… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Pathology #Pharmacogenomics #Pharmacology #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Role of image informatics in accelerating drug discovery and development

Role of image informatics in accelerating drug discovery and development By Robert Dunkle There is a new category of informatics that is proving itself essential to the acceleration of drug discovery and development. Image informatics is the systematic use of image data as a means to help interpret experiments and… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #PCR #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology

New Flash Imagers: Facilitating higher throughput functional GPCR assays

New Flash Imagers: Facilitating higher throughput functional GPCR assays By Dr John Comley The recent availability of tailored automation solutions that combine liquid handling at the reading position with the latest innovations in low light imaging technology are providing screeners with new tools for the measurement of high throughput flash… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Cell therapy #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology

PATCHERS vs SCREENERS: divergent opinion on high throughput electro-physiology

PATCHERS vs SCREENERS: divergent opinion on high throughput electro-physiology By Dr John Comley The prospect of enabling higher throughput electro-physiology (patch-clamping) has created much expectation from scientists within the ion channel community. Yet there are opposing views among traditional electro-physiologists and screeners as to the needed specification and the preferred… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Imaging #Lead discovery #Medicinal chemistry #Organic chemistry #Orphan drugs #PCR #Pharmacology #RNA #Screening #Stem cells #System biology #Target validation

High Throughput Screening using G-protein coupled receptors as the target plate-based and biochromatographic technologies

High Throughput Screening using G-protein coupled receptors as the target plate-based and biochromatographic technologies By Professor Irving W.Wainer, Dr Farideh Beigi and Dr Ruin Moaddel The G-protein coupled receptor (GPCR) family constitutes the largest class of cell surface receptors and GPCRs are the targets for more than 50% of the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Medicinal chemistry #Metabolomics #Molecular medicine #Pathology #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Molecular pathology and the art of drug design

Molecular pathology and the art of drug design By Dr Keith McCullagh The current explosion of interest in sophisticated genomic technologies, computerised robotics and high throughput screening of diverse molecular libraries appears to have been associated with a reduction in research productivity in recent years, as judged by the rate… Read More

#Archive

#Analysis #Biochemistry #Business #Chemistry #Clinical specialities #Drug development #Drug discovery #Lead discovery #Pharmacology #Preclinical #RNA

A business model for sustainable, strategic relationships

A business model for sustainable, strategic relationships By Dr Douglas J. Squires and Dr James E. McClurg Historically relationships between CROs and pharmaceutical and biotech companies, and the results of these relationships, have not met shared expectations for strategic value exchange. This article presents a business model for achieving a… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Biochemistry #Biomarkers #Business #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High throughput screening #In Silico Biology #Lead discovery #Microbiology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Target validation #Toxicology

Balancing Quantity and Quality in Drug Discovery

Balancing Quantity and Quality in Drug Discovery By Eva-Lotta Allan There is a need to innovate in order to stay ahead, a need to maximise the value of the R&D engine by increasing the flow of novel drug candidates and yet, reduce the time to market. Does access to more… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #Immunology #Lead discovery #Molecular medicine #Organic chemistry #Pharmacology #Preclinical #Regulatory #Stem cells #System biology

New Visions in Ophthalmic Drug Development

New Visions in Ophthalmic Drug Development By Dr Benjamin R. Yerxa, Dr Ward M. Peterson and Robin S.Whitsell Over the last 10 years we have seen the introduction of several new 'ophthalmology only' pharmaceutical products emerge such as Trusopt (dorzolamide, Merck) and Xalatan (latanoprost, Pharmacia). Innovative products such as these… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Lead optimisation #Molecular medicine #Organic chemistry #PCR #Pharmacology #Precision medicine #RNA #Screening #Target validation #Therapeutics #Toxicology

Better drugs by MICROARRAY

Better drugs by MICROARRAY By Dr Mark Schena Microarray analysis allows the elucidation of biological processes and pathways on a genomic scale. This revolutionary technology promises an unprecedented view of drug action and side reaction, the ability to identify drug targets and optimise lead compounds, the capacity to predict patient… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Automation / robotics #Business #Chemistry #Lead discovery #Pharmacology #Regulatory #RNA #System biology #Systems biology #Toxicology

Finding and minding R&D talent the hidden human cost of merger mania

Finding and minding R&D talent the hidden human cost of merger mania By Sue Harris This article examines the impact on R&D staff of the current economic uncertainty, the raft of mega-mergers and the growth of the biotech sector. Senior management repeatedly comment that finding, motivating and retaining talented individuals… Read More

#Archive